Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 374, Issue 9702, 2009, Pages 1694-1702

  Sur, Dipika ^a   Lopez, Anna Lena ^b   Kanungo, Suman ^a   Paisley, Allison ^b   Manna, Byomkesh ^a   Ali, Mohammad ^b   Niyogi, Swapan K ^a   Park, Jin Kyung ^b   Sarkar, Banawarilal ^a   Puri, Mahesh K ^b   Kim, Deok Ryun ^b   Deen, Jacqueline L ^b   Holmgren, Jan ^c   Carbis, Rodney ^b   Rao, Raman ^d   Van, Nguyen Thu ^e   Donner, Allan ^f   Ganguly, Nirmal K ^g,h   Nair, G Balakrish ^a   Bhattacharya, Sujit K ^a,g   Clemens, John D ^b   more..

^a NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^b International Vaccine Institute   (South Korea)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d Shantha Biotechnics Pvt Limited   (India)

^e Center for Research and Production of Vaccines and Biologicals   (Viet Nam)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^h NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; MODIFIED KILLED WHOLE CELL CHOLERA VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INDIA; INFANT; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIBRIO CHOLERAE;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHOLERA; CHOLERA VACCINES; CLUSTER ANALYSIS; DOUBLE-BLIND METHOD; ENDEMIC DISEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNIZATION SCHEDULE; INDIA; INFANT; KAPLAN-MEIER ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; SAFETY; VACCINES, INACTIVATED;

EID: 70449523583     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61297-6     Document Type: Article

References (28)

1. WHO. Cholera unveiled (2003), World Health Organization, Geneva
2. WHO. Cholera vaccines. Wkly Epidemiol Rec 76 (2001) 117-124
3. Chaignat C.L., and Monti V. Use of oral cholera vaccine in complex emergencies: what next? Summary report of an expert meeting and recommendations of WHO. J Health Popul Nutr 25 (2007) 244-261
4. Trach D.D., Clemens J.D., Ke N.T., et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349 (1997) 231-235
5. Thiem V.D., Deen J.L., von Seidlein L., et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine 24 (2006) 4297-4303
6. WHO Expert Committee on Biological Standardization. Fifty-second report (2004), World Health Organization, Geneva
7. Anh D.D., Canhdo G., Lopez A.L., et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25 (2007) 1149-1155
8. Mahalanabis D., Lopez A.L., Sur D., et al. A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India. PLoS One 3 (2008) e2323
9. Clemens J.D., Sack D.A., Harris J.R., et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 2 (1986) 124-127
10. Sanchez J.L., Vasquez B., Begue R.E., et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 344 (1994) 1273-1276
11. Taylor D.N., Cardenas V., Sanchez J.L., et al. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru. J Infect Dis 181 (2000) 1667-1673
12. Bopp C., Ries A., and Wells J. Laboratory methods for the diagnosis of epidemic dysentery and cholera (1999), Centers for Disease Control and Prevention, Atlanta, GA
13. WHO. The treatment of diarrhea: a manual for physicians and other senior health workers, 4th revision (2005), World Health Organization, Geneva
14. Expert Working Group (Efficacy) of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for industry. Clinical safety data management: definitions and standards for expedited reporting (March, 1995). http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129518.pdf (accessed Aug 11, 2009).
15. Liang K., and Zeger S. Longitudinal data analysis using generalized linear models. Biometrika 73 (1986) 13-22
16. Halloran M.E., Haber M., Longini I.M., and Struchiner C.J. Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol 133 (1991) 323-331
17. Miller R. Survival analysis (1981), John Wiley and Sons, New York
18. Reid N., and Crepeau H. Influence functions for proportional hazards regression. Biometrika 72 (1985) 1-9
19. Lin D., Wei L., and Ying Z. Checking the Cox model with cumulative sums of Martingale-based residuals. Biometrika 80 (1993) 557-572
20. Lin D.Y., and Wei L.J. The robust inference for the proportional hazards model. J Am Stat Assoc 84 (1989) 1074-1078
21. Peto R., Pike M.C., Armitage P., et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34 (1976) 585-612
22. Clemens J.D., Sack D.A., Harris J.R., et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335 (1990) 270-273
23. Altman D.G., and Bland J.M. Interaction revisited: the difference between two estimates. BMJ 326 (2003) 219
24. Vu D.T., Hossain M.M., Nguyen D.S., et al. Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam. J Health Popul Nutr 21 (2003) 304-308
25. Deen J.L., von Seidlein L., Sur D., et al. The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa. PLoS Negl Trop Dis 2 (2008) e173
26. Ali M., Emch M., von Seidlein L., et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366 (2005) 44-49
27. Ali M., Emch M., Yunus M., et al. Vaccine protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission. Pediatr Infect Dis J 27 (2008) 33-37
28. Longini I.M., Nizam A., Ali M., Yunus M., Shenvi N., and Clemens J.D. Controlling endemic cholera with oral vaccines. PLoS Med 4 (2007) e336